Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Use of Neratinib in HER2-Positive Breast Cancer

February 2nd 2018

Chemotherapy With Adjuvant Therapy in Breast Cancer

February 2nd 2018

Adjuvant Therapy Data for HER2-Positive Breast Cancer

February 2nd 2018

Breast Cancer: Factors to Consider for Adjuvant Therapy

February 2nd 2018

Treating Patients with HER2+ Breast Cancer: Impact of Cost

February 2nd 2018

Role for Neratinib Following Adjuvant Dual-Targeted HER2 Therapy

February 2nd 2018

Diarrhea Prophylaxis With Neratinib

February 2nd 2018

Optimal Timing for Neratinib

February 2nd 2018

Which Chemotherapy With Adjuvant Trastuzumab and Pertuzumab?

February 2nd 2018

Factors Influencing Adjuvant Therapy Use for HER2+ Breast Cancer

February 2nd 2018

The ExteNET Trial

February 2nd 2018

The APHINITY Trial

February 2nd 2018

Adjuvant Therapy for Early-Stage HER2+ Breast Cancer

February 2nd 2018

Tucatinib Combo Explored in HER2-Positive Breast Cancer

February 1st 2018

Rashmi K. Murthy, MD, MBE, discusses the role of tucatinib in CNS metastases for patients with HER2-positive breast cancer.

Dr. Francis Discusses the SOFT Trial for Breast Cancer

February 1st 2018

Prudence Francis, MD, Peter MacCallum Cancer Centre, discusses the SOFT trial for patients with breast cancer.

Developing Treatment for Invasive Lobular Carcinoma

January 31st 2018

Steffi Oesterreich, PhD, professor and vice chair of Precision and Translational Pharmacology, University of Pittsburgh, discusses developing treatment for patients with invasive lobular carcinoma (ILC).

Dr. Bardia on Sacituzumab Govitecan in Triple-Negative Breast Cancer

January 31st 2018

Aditya Bardia, MD, MPH, assistant professor of medicine, Harvard Medical School, attending physician, Medical Oncology, Massachusetts General Hospital, discusses a trial investigating sacituzumab govitecan for patients with triple-negative breast cancer (TNBC).

Enzalutamide Shows Early Promise in AR-Positive TNBC

January 30th 2018

Enzalutamide showed promising clinical activity in patients with androgen receptor–positive triple-negative breast cancer.

Dr. Carey Discusses the CALGB40502 Trial in TNBC

January 30th 2018

Lisa A. Carey, MD, professor, UNC Lineberger Comprehensive Cancer Center, discusses the CALGB 40502/NCCTG N063H trial in patients with triple-negative breast cancer (TNBC).

Dr. King on Role of Sentinel Lymph Node Biopsy in Breast Cancer

January 30th 2018

Tari King, MD, FACS, chief of Breast Surgery, Dana-Farber Cancer Institute, Brigham Women’s Cancer Center, discusses the role of sentinel lymph node biopsy in breast cancer.